Clinical and Translational Oncology

, Volume 18, Issue 8, pp 776–781 | Cite as

ATAD2 is overexpressed in gastric cancer and serves as an independent poor prognostic biomarker

  • M.- J. Zhang
  • C.- Z. Zhang
  • W.- J. Du
  • X.- Z. Yang
  • Z.- P. ChenEmail author
Research Article



ATPase family, AAA domain containing 2 (ATAD2) has been found overexpressed in various cancer types and correlated with malignant status and poor prognosis. However, little is known about the clinical significance of ATAD2 in gastric cancer patients. The aim of this study was to explore the clinical and prognostic significance of ATAD2 in gastric cancer.


The mRNA and protein levels expression of ATAD2 were detected in clinical tissue samples by qRT-PCR and immunohistochemistry, respectively. We examined the ATAD2 protein expression by immunohistochemistry. Furthermore, we analyzed the association between ATAD2 expression and clinicopathological features including prognosis in 166 gastric cancer samples.


In our results, ATAD2 mRNA and protein were highly expressed in gastric cancer samples. ATAD2 overexpression was correlated with advanced clinical stage, tumor depth, lymph node metastasis, and distant metastasis. According to the survival analysis, ATAD2 protein overexpression was a poor independent prognostic factor for gastric cancer patients.


In summary, ATAD2 could serve as a prognostic biomarker for gastric cancer patients.


ATAD2 Gastric cancer Prognosis Biomarker 




Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interests.

Ethical approval

All procedures performed in studies involving human participants were in accordance with Research Ethics Committee of Shandong Provincial Qianfoshan Hospital and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.


  1. 1.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi: 10.3322/caac.21262.CrossRefPubMedGoogle Scholar
  2. 2.
    Ye YW, Dong RZ, Zhou Y, Du CY, Wang CM, Fu H, et al. Prognostic analysis of familial gastric cancer in Chinese population. J Surg Oncol. 2011;104(1):76–82. doi: 10.1002/jso.21896.CrossRefPubMedGoogle Scholar
  3. 3.
    Wang CS, Hsieh CC, Chao TC, Jan YY, Jeng LB, Hwang TL, et al. Resectable gastric cancer: operative mortality and survival analysis. Chang Gung Med J. 2002;25(4):216–27.PubMedGoogle Scholar
  4. 4.
    Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L, et al. The incidences and mortalities of major cancers in China, 2009. Chin J Cancer. 2013;32(3):106–12. doi: 10.5732/cjc.013.10018.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. doi: 10.3322/caac.21254.CrossRefPubMedGoogle Scholar
  6. 6.
    Pasechnikov V, Chukov S, Fedorov E, Kikuste I, Leja M. Gastric cancer: prevention, screening and early diagnosis. WJG. 2014;20(38):13842–62. doi: 10.3748/wjg.v20.i38.13842.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Zou JX, Revenko AS, Li LB, Gemo AT, Chen HW. ANCCA, an estrogen-regulated AAA + ATPase coactivator for ERalpha, is required for coregulator occupancy and chromatin modification. Proc Natl Acad Sci USA. 2007;104(46):18067–72. doi: 10.1073/pnas.0705814104.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Ciro M, Prosperini E, Quarto M, Grazini U, Walfridsson J, McBlane F, et al. ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors. Cancer Res. 2009;69(21):8491–8. doi: 10.1158/0008-5472.CAN-09-2131.CrossRefPubMedGoogle Scholar
  9. 9.
    Leachman NT, Brellier F, Ferralli J, Chiquet-Ehrismann R, Tucker RP. ATAD2B is a phylogenetically conserved nuclear protein expressed during neuronal differentiation and tumorigenesis. Dev Growth Differ. 2010;52(9):747–55. doi: 10.1111/j.1440-169X.2010.01211.x.CrossRefPubMedGoogle Scholar
  10. 10.
    Zheng L, Li T, Zhang Y, Guo Y, Yao J, Dou L, et al. Oncogene ATAD2 promotes cell proliferation, invasion and migration in cervical cancer. Oncol Rep. 2015;33(5):2337–44. doi: 10.3892/or.2015.3867.PubMedGoogle Scholar
  11. 11.
    Wu G, Liu H, He H, Wang Y, Lu X, Yu Y, et al. miR-372 down-regulates the oncogene ATAD2 to influence hepatocellular carcinoma proliferation and metastasis. BMC Cancer. 2014;14:107. doi: 10.1186/1471-2407-14-107.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Boussouar F, Jamshidikia M, Morozumi Y, Rousseaux S, Khochbin S. Malignant genome reprogramming by ATAD2. Biochim Biophys Acta. 2013;1829(10):1010–4. doi: 10.1016/j.bbagrm.2013.06.003.CrossRefPubMedGoogle Scholar
  13. 13.
    Salhia B, Kiefer J, Ross JT, Metapally R, Martinez RA, Johnson KN, et al. Integrated genomic and epigenomic analysis of breast cancer brain metastasis. PLoS One. 2014;9(1):e85448. doi: 10.1371/journal.pone.0085448.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Kalashnikova EV, Revenko AS, Gemo AT, Andrews NP, Tepper CG, Zou JX, et al. ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. Cancer Res. 2010;70(22):9402–12. doi: 10.1158/0008-5472.CAN-10-1199.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Caron C, Lestrat C, Marsal S, Escoffier E, Curtet S, Virolle V, et al. Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers. Oncogene. 2010;29(37):5171–81. doi: 10.1038/onc.2010.259.CrossRefPubMedGoogle Scholar
  16. 16.
    Hsia EY, Kalashnikova EV, Revenko AS, Zou JX, Borowsky AD, Chen HW. Deregulated E2F and the AAA + coregulator ANCCA drive proto-oncogene ACTR/AIB1 overexpression in breast cancer. MCR. 2010;8(2):183–93. doi: 10.1158/1541-7786.MCR-09-0095.CrossRefPubMedGoogle Scholar
  17. 17.
    Wu G, Lu X, Wang Y, He H, Meng X, Xia S, et al. Epigenetic high regulation of ATAD2 regulates the Hh pathway in human hepatocellular carcinoma. Int J Oncol. 2014;45(1):351–61. doi: 10.3892/ijo.2014.2416.PubMedGoogle Scholar
  18. 18.
    Hwang HW, Ha SY, Bang H, Park CK. ATAD2 as a Poor Prognostic Marker for Hepatocellular Carcinoma after Curative Resection. Cancer Res Treatment Off J Korean Cancer Assoc. 2015;. doi: 10.4143/crt.2014.177.Google Scholar
  19. 19.
    Zhang Y, Sun Y, Li Y, Fang Z, Wang R, Pan Y, et al. ANCCA protein expression is a novel independent poor prognostic marker in surgically resected lung adenocarcinoma. Ann Surg Oncol. 2013;20(Suppl 3):S577–82. doi: 10.1245/s10434-013-3027-1.CrossRefPubMedGoogle Scholar
  20. 20.
    Wan WN, Zhang YX, Wang XM, Liu YJ, Zhang YQ, Que YH, et al. ATAD2 is highly expressed in ovarian carcinomas and indicates poor prognosis. APJCP. 2014;15(6):2777–83.PubMedGoogle Scholar
  21. 21.
    Wrzeszczynski KO, Varadan V, Byrnes J, Lum E, Kamalakaran S, Levine DA, et al. Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer. PLoS One. 2011;6(12):e28503. doi: 10.1371/journal.pone.0028503.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Raeder MB, Birkeland E, Trovik J, Krakstad C, Shehata S, Schumacher S, et al. Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. PLoS ONE. 2013;8(2):e54873. doi: 10.1371/journal.pone.0054873.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–11. doi: 10.1038/35000501.CrossRefPubMedGoogle Scholar
  24. 24.
    Zou JX, Guo L, Revenko AS, Tepper CG, Gemo AT, Kung HJ, et al. Androgen-induced coactivator ANCCA mediates specific androgen receptor signaling in prostate cancer. Cancer Res. 2009;69(8):3339–46. doi: 10.1158/0008-5472.CAN-08-3440.CrossRefPubMedGoogle Scholar
  25. 25.
    Fellenberg J, Bernd L, Delling G, Witte D, Zahlten-Hinguranage A. Prognostic significance of drug-regulated genes in high-grade osteosarcoma. Modern Pathol Off J United States and Canadian Acad Pathol. 2007;20(10):1085–94. doi: 10.1038/modpathol.3800937.CrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2015

Authors and Affiliations

  • M.- J. Zhang
    • 1
  • C.- Z. Zhang
    • 1
  • W.- J. Du
    • 1
  • X.- Z. Yang
    • 1
  • Z.- P. Chen
    • 1
    Email author
  1. 1.Department of GastroenterologyShandong Provincial Qianfoshan Hospital, Shandong UniversityJinanChina

Personalised recommendations